Acumen Pharmaceuticals, Inc. Common Stock (ABOS) Stock
Key stats
- Market cap
- $16.64M
- Price / Earnings ratio
- -0.2x
- EPS (TTM)
- -$1.54
- Volume
- Loading
- 52-week high
- $3.60
- 52-week low
- $0.19
Source: third-party data provider, as of November 13, 2026
Compare with ABOS
Recent news

Acumen Pharmaceuticals Q3 Earnings Call Highlights
Acumen Pharmaceuticals Q3 Earnings Call Highlights
ABOS

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
ABOS

Acumen Pharmaceuticals Q2 Earnings Call Highlights
Acumen Pharmaceuticals Q2 Earnings Call Highlights
ABOS

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
ABOS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 21.61
- MACD 12/26/9
- -0.55
- EMA 9 of MACD
- -0.44
- MACD histogram
- -0.10
- SMA 50
- $1.96
- Price below SMA 50
- EMA 50
- $1.66
- Price below EMA 50
- SMA 200
- $2.43
- Price below SMA 200
- EMA 200
- $2.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Acumen Pharmaceuticals Q3 Earnings Call Highlights
Acumen Pharmaceuticals Q3 Earnings Call Highlights
ABOS

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
ABOS

Acumen Pharmaceuticals Q2 Earnings Call Highlights
Acumen Pharmaceuticals Q2 Earnings Call Highlights
ABOS

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
ABOS

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
ABOS

Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
ABOS

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
ABOS

Acumen Pharmaceuticals Q1 Earnings Call Highlights
Acumen Pharmaceuticals Q1 Earnings Call Highlights
ABOS

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ABOS

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
ABOS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Acumen Pharmaceuticals, Inc. Common Stock
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel J. O'Connell M.B.A. | CEO & Director | 1970 |
| Mr. Matt Zuga | CFO & Chief Business Officer | — |
| Mr. Russell Barton M.S. | Chief Operating Officer | 1959 |
| Dr. James Doherty Ph.D. | President & Chief Development Officer | 1968 |
| Dr. Grant A. Krafft Ph.D. | Co-Founder | — |
| Dr. Caleb E. Finch Ph.D. | Co-Founder | — |
| Dr. William L. Klein Ph.D. | Co-Founder | — |
| Ms. Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller | — |
| Ms. Alex Braun M.B.A. | VP & Head of Investor Relations | — |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 21.61
- MACD 12/26/9
- -0.55
- EMA 9 of MACD
- -0.44
- MACD histogram
- -0.10
- SMA 50
- $1.96
- Price below SMA 50
- EMA 50
- $1.66
- Price below EMA 50
- SMA 200
- $2.43
- Price below SMA 200
- EMA 200
- $2.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $1.00
- Average
- $1.00
- High
- $1.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.8 | +21.2 | -28.5 | -6.3 | +9.2 | +6.4 | -17.0 | +30.7 | -24.0 | -89.9 | -4.2 |



